Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population
Malignant rhabdoid tumors (MRT) predominantly affect infants and young children. Patients below six months of age represent a particularly therapeutically challenging group. Toxicity to developing organ sites limits intensity of treatment. Information on prognostic factors, genetics, toxicity of tre...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-04, Vol.14 (9), p.2185 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 2185 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Nemes, Karolina Johann, Pascal D Steinbügl, Mona Gruhle, Miriam Bens, Susanne Kachanov, Denis Teleshova, Margarita Hauser, Peter Simon, Thorsten Tippelt, Stephan Eberl, Wolfgang Chada, Martin Lopez, Vicente Santa-Maria Grigull, Lorenz Hernáiz-Driever, Pablo Eyrich, Matthias Pears, Jane Milde, Till Reinhard, Harald Leipold, Alfred van de Wetering, Marianne Gil-da-Costa, Maria João Ebetsberger-Dachs, Georg Kerl, Kornelius Lemmer, Andreas Boztug, Heidrun Furtwängler, Rhoikos Kordes, Uwe Vokuhl, Christian Hasselblatt, Martin Bison, Brigitte Kröncke, Thomas Melchior, Patrick Timmermann, Beate Gerss, Joachim Siebert, Reiner Frühwald, Michael C |
| description | Malignant rhabdoid tumors (MRT) predominantly affect infants and young children. Patients below six months of age represent a particularly therapeutically challenging group. Toxicity to developing organ sites limits intensity of treatment. Information on prognostic factors, genetics, toxicity of treatment and long-term outcomes is sparse.
Clinical, genetic, and treatment data of 100 patients (aged below 6 months at diagnosis) from 13 European countries were analyzed (2005-2020). Tumors and matching blood samples were examined for
mutations using FISH, MLPA and Sanger sequencing. DNA methylation subgroups (ATRT-TYR, ATRT-SHH, and ATRT-MYC) were determined using 450 k / 850 k-profiling.
A total of 45 patients presented with ATRT, 29 with extracranial, extrarenal (eMRT) and 9 with renal rhabdoid tumors (RTK). Seventeen patients demonstrated synchronous tumors (SYN). Metastases (M+) were present in 27% (26/97) at diagnosis. A germline mutation (GLM) was detected in 55% (47/86). DNA methylation subgrouping was available in 50% (31 / 62) with ATRT or SYN; for eMRT, methylation-based subgrouping was not performed. The 5-year overall (OS) and event free survival (EFS) rates were 23.5 ± 4.6% and 19 ± 4.1%, respectively. Male sex (11 ± 5% vs. 35.8 ± 7.4%), M+ stage (6.1 ± 5.4% vs. 36.2 ± 7.4%), presence of SYN (7.1 ± 6.9% vs. 26.6 ± 5.3%) and GLM (7.7 ± 4.2% vs. 45.7 ± 8.6%) were significant prognostic factors for 5-year OS. Molecular subgrouping and survival analyses confirm a previously described survival advantage for ATRT-TYR. In an adjusted multivariate model, clinical factors that favorably influence the prognosis were female sex, localized stage, absence of a GLM and maintenance therapy.
In this cohort of homogenously treated infants with MRT, significant predictors of outcome were sex, M-stage, GLM and maintenance therapy. We confirm the need to stratify which patient groups benefit from multimodal treatment, and which need novel therapeutic strategies. Biomarker-driven tailored trials may be a key option. |
| doi_str_mv | 10.3390/cancers14092185 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9100752</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2664796092</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-8fbc650b7742b9dd2069e0062f62b082872ba2ade33f6ebeff6bb356e09267b3</originalsourceid><addsrcrecordid>eNplkkFP3DAQhaOqVUGUc2-VpV7oIeDYiZ30UCldbQEJClqFc2Qnk8TIa29tp3R_Vv9hvUARpb54JH_vjZ89SfI-w8eUVvikE6YD57McVyQri1fJPsGcpIxV-etn9V5y6P0tjovSjDP-NtmjRcEKmtH95Pe5GYQJHgnTo-9wJ60zHt2pMKE6bDeqExo14ESwqkerSch-VzTz2jqPjupm1Xy6ly5_BSc6J4yKgkuh1Wii7f8KuNwplEFhArS8SVdn9Ve0glH54LafUY1ujPoxw73nYhJagxmVGdG13cxaBGXNu-TNILSHw8f9IGm-LZvFWXpxdXq-qC_SLidZSMtBdqzAkvOcyKrvCWYVYMzIwIjEJSk5kYKIHigdGEgYBiYlLRjEx2Rc0oPky4PtZpZr6DswMaBuN06thdu2Vqj23xOjpna0P9sqw5gXJBocPRo4GxP50K6V70BrYcDOviWM5bxisV1EP75Ab-3sTEy3o0jFi7wsInXyQHXOeu9geLpMhtvdQLQvBiIqPjzP8MT__X76B3XrtBA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2662975485</pqid></control><display><type>article</type><title>Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Nemes, Karolina ; Johann, Pascal D ; Steinbügl, Mona ; Gruhle, Miriam ; Bens, Susanne ; Kachanov, Denis ; Teleshova, Margarita ; Hauser, Peter ; Simon, Thorsten ; Tippelt, Stephan ; Eberl, Wolfgang ; Chada, Martin ; Lopez, Vicente Santa-Maria ; Grigull, Lorenz ; Hernáiz-Driever, Pablo ; Eyrich, Matthias ; Pears, Jane ; Milde, Till ; Reinhard, Harald ; Leipold, Alfred ; van de Wetering, Marianne ; Gil-da-Costa, Maria João ; Ebetsberger-Dachs, Georg ; Kerl, Kornelius ; Lemmer, Andreas ; Boztug, Heidrun ; Furtwängler, Rhoikos ; Kordes, Uwe ; Vokuhl, Christian ; Hasselblatt, Martin ; Bison, Brigitte ; Kröncke, Thomas ; Melchior, Patrick ; Timmermann, Beate ; Gerss, Joachim ; Siebert, Reiner ; Frühwald, Michael C</creator><creatorcontrib>Nemes, Karolina ; Johann, Pascal D ; Steinbügl, Mona ; Gruhle, Miriam ; Bens, Susanne ; Kachanov, Denis ; Teleshova, Margarita ; Hauser, Peter ; Simon, Thorsten ; Tippelt, Stephan ; Eberl, Wolfgang ; Chada, Martin ; Lopez, Vicente Santa-Maria ; Grigull, Lorenz ; Hernáiz-Driever, Pablo ; Eyrich, Matthias ; Pears, Jane ; Milde, Till ; Reinhard, Harald ; Leipold, Alfred ; van de Wetering, Marianne ; Gil-da-Costa, Maria João ; Ebetsberger-Dachs, Georg ; Kerl, Kornelius ; Lemmer, Andreas ; Boztug, Heidrun ; Furtwängler, Rhoikos ; Kordes, Uwe ; Vokuhl, Christian ; Hasselblatt, Martin ; Bison, Brigitte ; Kröncke, Thomas ; Melchior, Patrick ; Timmermann, Beate ; Gerss, Joachim ; Siebert, Reiner ; Frühwald, Michael C</creatorcontrib><description>Malignant rhabdoid tumors (MRT) predominantly affect infants and young children. Patients below six months of age represent a particularly therapeutically challenging group. Toxicity to developing organ sites limits intensity of treatment. Information on prognostic factors, genetics, toxicity of treatment and long-term outcomes is sparse.
Clinical, genetic, and treatment data of 100 patients (aged below 6 months at diagnosis) from 13 European countries were analyzed (2005-2020). Tumors and matching blood samples were examined for
mutations using FISH, MLPA and Sanger sequencing. DNA methylation subgroups (ATRT-TYR, ATRT-SHH, and ATRT-MYC) were determined using 450 k / 850 k-profiling.
A total of 45 patients presented with ATRT, 29 with extracranial, extrarenal (eMRT) and 9 with renal rhabdoid tumors (RTK). Seventeen patients demonstrated synchronous tumors (SYN). Metastases (M+) were present in 27% (26/97) at diagnosis. A germline mutation (GLM) was detected in 55% (47/86). DNA methylation subgrouping was available in 50% (31 / 62) with ATRT or SYN; for eMRT, methylation-based subgrouping was not performed. The 5-year overall (OS) and event free survival (EFS) rates were 23.5 ± 4.6% and 19 ± 4.1%, respectively. Male sex (11 ± 5% vs. 35.8 ± 7.4%), M+ stage (6.1 ± 5.4% vs. 36.2 ± 7.4%), presence of SYN (7.1 ± 6.9% vs. 26.6 ± 5.3%) and GLM (7.7 ± 4.2% vs. 45.7 ± 8.6%) were significant prognostic factors for 5-year OS. Molecular subgrouping and survival analyses confirm a previously described survival advantage for ATRT-TYR. In an adjusted multivariate model, clinical factors that favorably influence the prognosis were female sex, localized stage, absence of a GLM and maintenance therapy.
In this cohort of homogenously treated infants with MRT, significant predictors of outcome were sex, M-stage, GLM and maintenance therapy. We confirm the need to stratify which patient groups benefit from multimodal treatment, and which need novel therapeutic strategies. Biomarker-driven tailored trials may be a key option.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14092185</identifier><identifier>PMID: 35565313</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Age ; Biomarkers ; Chemotherapy ; Children ; Clinical trials ; Diagnosis ; DNA methylation ; DNA sequencing ; Females ; Infants ; Kidneys ; Lymphatic system ; Medical prognosis ; Metastases ; Metastasis ; Mutation ; Myc protein ; Neonates ; Newborn babies ; Patients ; Physiology ; Prognosis ; Radiation therapy ; Sex ; Survival ; Toxicity ; Tumors</subject><ispartof>Cancers, 2022-04, Vol.14 (9), p.2185</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-8fbc650b7742b9dd2069e0062f62b082872ba2ade33f6ebeff6bb356e09267b3</citedby><cites>FETCH-LOGICAL-c421t-8fbc650b7742b9dd2069e0062f62b082872ba2ade33f6ebeff6bb356e09267b3</cites><orcidid>0000-0003-4889-1036 ; 0000-0001-8807-2874 ; 0000-0002-3425-8451 ; 0000-0003-3135-3872 ; 0000-0002-1967-8343 ; 0000-0003-3489-683X ; 0000-0002-8237-1854 ; 0000-0001-8791-9914 ; 0000-0001-6375-2320</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100752/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100752/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35565313$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nemes, Karolina</creatorcontrib><creatorcontrib>Johann, Pascal D</creatorcontrib><creatorcontrib>Steinbügl, Mona</creatorcontrib><creatorcontrib>Gruhle, Miriam</creatorcontrib><creatorcontrib>Bens, Susanne</creatorcontrib><creatorcontrib>Kachanov, Denis</creatorcontrib><creatorcontrib>Teleshova, Margarita</creatorcontrib><creatorcontrib>Hauser, Peter</creatorcontrib><creatorcontrib>Simon, Thorsten</creatorcontrib><creatorcontrib>Tippelt, Stephan</creatorcontrib><creatorcontrib>Eberl, Wolfgang</creatorcontrib><creatorcontrib>Chada, Martin</creatorcontrib><creatorcontrib>Lopez, Vicente Santa-Maria</creatorcontrib><creatorcontrib>Grigull, Lorenz</creatorcontrib><creatorcontrib>Hernáiz-Driever, Pablo</creatorcontrib><creatorcontrib>Eyrich, Matthias</creatorcontrib><creatorcontrib>Pears, Jane</creatorcontrib><creatorcontrib>Milde, Till</creatorcontrib><creatorcontrib>Reinhard, Harald</creatorcontrib><creatorcontrib>Leipold, Alfred</creatorcontrib><creatorcontrib>van de Wetering, Marianne</creatorcontrib><creatorcontrib>Gil-da-Costa, Maria João</creatorcontrib><creatorcontrib>Ebetsberger-Dachs, Georg</creatorcontrib><creatorcontrib>Kerl, Kornelius</creatorcontrib><creatorcontrib>Lemmer, Andreas</creatorcontrib><creatorcontrib>Boztug, Heidrun</creatorcontrib><creatorcontrib>Furtwängler, Rhoikos</creatorcontrib><creatorcontrib>Kordes, Uwe</creatorcontrib><creatorcontrib>Vokuhl, Christian</creatorcontrib><creatorcontrib>Hasselblatt, Martin</creatorcontrib><creatorcontrib>Bison, Brigitte</creatorcontrib><creatorcontrib>Kröncke, Thomas</creatorcontrib><creatorcontrib>Melchior, Patrick</creatorcontrib><creatorcontrib>Timmermann, Beate</creatorcontrib><creatorcontrib>Gerss, Joachim</creatorcontrib><creatorcontrib>Siebert, Reiner</creatorcontrib><creatorcontrib>Frühwald, Michael C</creatorcontrib><title>Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Malignant rhabdoid tumors (MRT) predominantly affect infants and young children. Patients below six months of age represent a particularly therapeutically challenging group. Toxicity to developing organ sites limits intensity of treatment. Information on prognostic factors, genetics, toxicity of treatment and long-term outcomes is sparse.
Clinical, genetic, and treatment data of 100 patients (aged below 6 months at diagnosis) from 13 European countries were analyzed (2005-2020). Tumors and matching blood samples were examined for
mutations using FISH, MLPA and Sanger sequencing. DNA methylation subgroups (ATRT-TYR, ATRT-SHH, and ATRT-MYC) were determined using 450 k / 850 k-profiling.
A total of 45 patients presented with ATRT, 29 with extracranial, extrarenal (eMRT) and 9 with renal rhabdoid tumors (RTK). Seventeen patients demonstrated synchronous tumors (SYN). Metastases (M+) were present in 27% (26/97) at diagnosis. A germline mutation (GLM) was detected in 55% (47/86). DNA methylation subgrouping was available in 50% (31 / 62) with ATRT or SYN; for eMRT, methylation-based subgrouping was not performed. The 5-year overall (OS) and event free survival (EFS) rates were 23.5 ± 4.6% and 19 ± 4.1%, respectively. Male sex (11 ± 5% vs. 35.8 ± 7.4%), M+ stage (6.1 ± 5.4% vs. 36.2 ± 7.4%), presence of SYN (7.1 ± 6.9% vs. 26.6 ± 5.3%) and GLM (7.7 ± 4.2% vs. 45.7 ± 8.6%) were significant prognostic factors for 5-year OS. Molecular subgrouping and survival analyses confirm a previously described survival advantage for ATRT-TYR. In an adjusted multivariate model, clinical factors that favorably influence the prognosis were female sex, localized stage, absence of a GLM and maintenance therapy.
In this cohort of homogenously treated infants with MRT, significant predictors of outcome were sex, M-stage, GLM and maintenance therapy. We confirm the need to stratify which patient groups benefit from multimodal treatment, and which need novel therapeutic strategies. Biomarker-driven tailored trials may be a key option.</description><subject>Age</subject><subject>Biomarkers</subject><subject>Chemotherapy</subject><subject>Children</subject><subject>Clinical trials</subject><subject>Diagnosis</subject><subject>DNA methylation</subject><subject>DNA sequencing</subject><subject>Females</subject><subject>Infants</subject><subject>Kidneys</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Myc protein</subject><subject>Neonates</subject><subject>Newborn babies</subject><subject>Patients</subject><subject>Physiology</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Sex</subject><subject>Survival</subject><subject>Toxicity</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNplkkFP3DAQhaOqVUGUc2-VpV7oIeDYiZ30UCldbQEJClqFc2Qnk8TIa29tp3R_Vv9hvUARpb54JH_vjZ89SfI-w8eUVvikE6YD57McVyQri1fJPsGcpIxV-etn9V5y6P0tjovSjDP-NtmjRcEKmtH95Pe5GYQJHgnTo-9wJ60zHt2pMKE6bDeqExo14ESwqkerSch-VzTz2jqPjupm1Xy6ly5_BSc6J4yKgkuh1Wii7f8KuNwplEFhArS8SVdn9Ve0glH54LafUY1ujPoxw73nYhJagxmVGdG13cxaBGXNu-TNILSHw8f9IGm-LZvFWXpxdXq-qC_SLidZSMtBdqzAkvOcyKrvCWYVYMzIwIjEJSk5kYKIHigdGEgYBiYlLRjEx2Rc0oPky4PtZpZr6DswMaBuN06thdu2Vqj23xOjpna0P9sqw5gXJBocPRo4GxP50K6V70BrYcDOviWM5bxisV1EP75Ab-3sTEy3o0jFi7wsInXyQHXOeu9geLpMhtvdQLQvBiIqPjzP8MT__X76B3XrtBA</recordid><startdate>20220427</startdate><enddate>20220427</enddate><creator>Nemes, Karolina</creator><creator>Johann, Pascal D</creator><creator>Steinbügl, Mona</creator><creator>Gruhle, Miriam</creator><creator>Bens, Susanne</creator><creator>Kachanov, Denis</creator><creator>Teleshova, Margarita</creator><creator>Hauser, Peter</creator><creator>Simon, Thorsten</creator><creator>Tippelt, Stephan</creator><creator>Eberl, Wolfgang</creator><creator>Chada, Martin</creator><creator>Lopez, Vicente Santa-Maria</creator><creator>Grigull, Lorenz</creator><creator>Hernáiz-Driever, Pablo</creator><creator>Eyrich, Matthias</creator><creator>Pears, Jane</creator><creator>Milde, Till</creator><creator>Reinhard, Harald</creator><creator>Leipold, Alfred</creator><creator>van de Wetering, Marianne</creator><creator>Gil-da-Costa, Maria João</creator><creator>Ebetsberger-Dachs, Georg</creator><creator>Kerl, Kornelius</creator><creator>Lemmer, Andreas</creator><creator>Boztug, Heidrun</creator><creator>Furtwängler, Rhoikos</creator><creator>Kordes, Uwe</creator><creator>Vokuhl, Christian</creator><creator>Hasselblatt, Martin</creator><creator>Bison, Brigitte</creator><creator>Kröncke, Thomas</creator><creator>Melchior, Patrick</creator><creator>Timmermann, Beate</creator><creator>Gerss, Joachim</creator><creator>Siebert, Reiner</creator><creator>Frühwald, Michael C</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4889-1036</orcidid><orcidid>https://orcid.org/0000-0001-8807-2874</orcidid><orcidid>https://orcid.org/0000-0002-3425-8451</orcidid><orcidid>https://orcid.org/0000-0003-3135-3872</orcidid><orcidid>https://orcid.org/0000-0002-1967-8343</orcidid><orcidid>https://orcid.org/0000-0003-3489-683X</orcidid><orcidid>https://orcid.org/0000-0002-8237-1854</orcidid><orcidid>https://orcid.org/0000-0001-8791-9914</orcidid><orcidid>https://orcid.org/0000-0001-6375-2320</orcidid></search><sort><creationdate>20220427</creationdate><title>Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population</title><author>Nemes, Karolina ; Johann, Pascal D ; Steinbügl, Mona ; Gruhle, Miriam ; Bens, Susanne ; Kachanov, Denis ; Teleshova, Margarita ; Hauser, Peter ; Simon, Thorsten ; Tippelt, Stephan ; Eberl, Wolfgang ; Chada, Martin ; Lopez, Vicente Santa-Maria ; Grigull, Lorenz ; Hernáiz-Driever, Pablo ; Eyrich, Matthias ; Pears, Jane ; Milde, Till ; Reinhard, Harald ; Leipold, Alfred ; van de Wetering, Marianne ; Gil-da-Costa, Maria João ; Ebetsberger-Dachs, Georg ; Kerl, Kornelius ; Lemmer, Andreas ; Boztug, Heidrun ; Furtwängler, Rhoikos ; Kordes, Uwe ; Vokuhl, Christian ; Hasselblatt, Martin ; Bison, Brigitte ; Kröncke, Thomas ; Melchior, Patrick ; Timmermann, Beate ; Gerss, Joachim ; Siebert, Reiner ; Frühwald, Michael C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-8fbc650b7742b9dd2069e0062f62b082872ba2ade33f6ebeff6bb356e09267b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>Biomarkers</topic><topic>Chemotherapy</topic><topic>Children</topic><topic>Clinical trials</topic><topic>Diagnosis</topic><topic>DNA methylation</topic><topic>DNA sequencing</topic><topic>Females</topic><topic>Infants</topic><topic>Kidneys</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Myc protein</topic><topic>Neonates</topic><topic>Newborn babies</topic><topic>Patients</topic><topic>Physiology</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Sex</topic><topic>Survival</topic><topic>Toxicity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nemes, Karolina</creatorcontrib><creatorcontrib>Johann, Pascal D</creatorcontrib><creatorcontrib>Steinbügl, Mona</creatorcontrib><creatorcontrib>Gruhle, Miriam</creatorcontrib><creatorcontrib>Bens, Susanne</creatorcontrib><creatorcontrib>Kachanov, Denis</creatorcontrib><creatorcontrib>Teleshova, Margarita</creatorcontrib><creatorcontrib>Hauser, Peter</creatorcontrib><creatorcontrib>Simon, Thorsten</creatorcontrib><creatorcontrib>Tippelt, Stephan</creatorcontrib><creatorcontrib>Eberl, Wolfgang</creatorcontrib><creatorcontrib>Chada, Martin</creatorcontrib><creatorcontrib>Lopez, Vicente Santa-Maria</creatorcontrib><creatorcontrib>Grigull, Lorenz</creatorcontrib><creatorcontrib>Hernáiz-Driever, Pablo</creatorcontrib><creatorcontrib>Eyrich, Matthias</creatorcontrib><creatorcontrib>Pears, Jane</creatorcontrib><creatorcontrib>Milde, Till</creatorcontrib><creatorcontrib>Reinhard, Harald</creatorcontrib><creatorcontrib>Leipold, Alfred</creatorcontrib><creatorcontrib>van de Wetering, Marianne</creatorcontrib><creatorcontrib>Gil-da-Costa, Maria João</creatorcontrib><creatorcontrib>Ebetsberger-Dachs, Georg</creatorcontrib><creatorcontrib>Kerl, Kornelius</creatorcontrib><creatorcontrib>Lemmer, Andreas</creatorcontrib><creatorcontrib>Boztug, Heidrun</creatorcontrib><creatorcontrib>Furtwängler, Rhoikos</creatorcontrib><creatorcontrib>Kordes, Uwe</creatorcontrib><creatorcontrib>Vokuhl, Christian</creatorcontrib><creatorcontrib>Hasselblatt, Martin</creatorcontrib><creatorcontrib>Bison, Brigitte</creatorcontrib><creatorcontrib>Kröncke, Thomas</creatorcontrib><creatorcontrib>Melchior, Patrick</creatorcontrib><creatorcontrib>Timmermann, Beate</creatorcontrib><creatorcontrib>Gerss, Joachim</creatorcontrib><creatorcontrib>Siebert, Reiner</creatorcontrib><creatorcontrib>Frühwald, Michael C</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nemes, Karolina</au><au>Johann, Pascal D</au><au>Steinbügl, Mona</au><au>Gruhle, Miriam</au><au>Bens, Susanne</au><au>Kachanov, Denis</au><au>Teleshova, Margarita</au><au>Hauser, Peter</au><au>Simon, Thorsten</au><au>Tippelt, Stephan</au><au>Eberl, Wolfgang</au><au>Chada, Martin</au><au>Lopez, Vicente Santa-Maria</au><au>Grigull, Lorenz</au><au>Hernáiz-Driever, Pablo</au><au>Eyrich, Matthias</au><au>Pears, Jane</au><au>Milde, Till</au><au>Reinhard, Harald</au><au>Leipold, Alfred</au><au>van de Wetering, Marianne</au><au>Gil-da-Costa, Maria João</au><au>Ebetsberger-Dachs, Georg</au><au>Kerl, Kornelius</au><au>Lemmer, Andreas</au><au>Boztug, Heidrun</au><au>Furtwängler, Rhoikos</au><au>Kordes, Uwe</au><au>Vokuhl, Christian</au><au>Hasselblatt, Martin</au><au>Bison, Brigitte</au><au>Kröncke, Thomas</au><au>Melchior, Patrick</au><au>Timmermann, Beate</au><au>Gerss, Joachim</au><au>Siebert, Reiner</au><au>Frühwald, Michael C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-04-27</date><risdate>2022</risdate><volume>14</volume><issue>9</issue><spage>2185</spage><pages>2185-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Malignant rhabdoid tumors (MRT) predominantly affect infants and young children. Patients below six months of age represent a particularly therapeutically challenging group. Toxicity to developing organ sites limits intensity of treatment. Information on prognostic factors, genetics, toxicity of treatment and long-term outcomes is sparse.
Clinical, genetic, and treatment data of 100 patients (aged below 6 months at diagnosis) from 13 European countries were analyzed (2005-2020). Tumors and matching blood samples were examined for
mutations using FISH, MLPA and Sanger sequencing. DNA methylation subgroups (ATRT-TYR, ATRT-SHH, and ATRT-MYC) were determined using 450 k / 850 k-profiling.
A total of 45 patients presented with ATRT, 29 with extracranial, extrarenal (eMRT) and 9 with renal rhabdoid tumors (RTK). Seventeen patients demonstrated synchronous tumors (SYN). Metastases (M+) were present in 27% (26/97) at diagnosis. A germline mutation (GLM) was detected in 55% (47/86). DNA methylation subgrouping was available in 50% (31 / 62) with ATRT or SYN; for eMRT, methylation-based subgrouping was not performed. The 5-year overall (OS) and event free survival (EFS) rates were 23.5 ± 4.6% and 19 ± 4.1%, respectively. Male sex (11 ± 5% vs. 35.8 ± 7.4%), M+ stage (6.1 ± 5.4% vs. 36.2 ± 7.4%), presence of SYN (7.1 ± 6.9% vs. 26.6 ± 5.3%) and GLM (7.7 ± 4.2% vs. 45.7 ± 8.6%) were significant prognostic factors for 5-year OS. Molecular subgrouping and survival analyses confirm a previously described survival advantage for ATRT-TYR. In an adjusted multivariate model, clinical factors that favorably influence the prognosis were female sex, localized stage, absence of a GLM and maintenance therapy.
In this cohort of homogenously treated infants with MRT, significant predictors of outcome were sex, M-stage, GLM and maintenance therapy. We confirm the need to stratify which patient groups benefit from multimodal treatment, and which need novel therapeutic strategies. Biomarker-driven tailored trials may be a key option.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35565313</pmid><doi>10.3390/cancers14092185</doi><orcidid>https://orcid.org/0000-0003-4889-1036</orcidid><orcidid>https://orcid.org/0000-0001-8807-2874</orcidid><orcidid>https://orcid.org/0000-0002-3425-8451</orcidid><orcidid>https://orcid.org/0000-0003-3135-3872</orcidid><orcidid>https://orcid.org/0000-0002-1967-8343</orcidid><orcidid>https://orcid.org/0000-0003-3489-683X</orcidid><orcidid>https://orcid.org/0000-0002-8237-1854</orcidid><orcidid>https://orcid.org/0000-0001-8791-9914</orcidid><orcidid>https://orcid.org/0000-0001-6375-2320</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-04, Vol.14 (9), p.2185 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9100752 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Age Biomarkers Chemotherapy Children Clinical trials Diagnosis DNA methylation DNA sequencing Females Infants Kidneys Lymphatic system Medical prognosis Metastases Metastasis Mutation Myc protein Neonates Newborn babies Patients Physiology Prognosis Radiation therapy Sex Survival Toxicity Tumors |
| title | Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T02%3A22%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infants%20and%20Newborns%20with%20Atypical%20Teratoid%20Rhabdoid%20Tumors%20(ATRT)%20and%20Extracranial%20Malignant%20Rhabdoid%20Tumors%20(eMRT)%20in%20the%20EU-RHAB%20Registry:%20A%20Unique%20and%20Challenging%20Population&rft.jtitle=Cancers&rft.au=Nemes,%20Karolina&rft.date=2022-04-27&rft.volume=14&rft.issue=9&rft.spage=2185&rft.pages=2185-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14092185&rft_dat=%3Cproquest_pubme%3E2664796092%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2662975485&rft_id=info:pmid/35565313&rfr_iscdi=true |